Skip to main content

Table 1 Patients characteristics.

From: Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

 

ALL PATIENTS

TP-TREATED GROUP

PC/PAC-TREATED GROUP

 

N = 435

N = 191

N = 244

Age (years)

   

Range

20-78

20-78

24-77

Mean

54.3

54.9

53.9

FIGO stage

   

IIB, IIC

27 (6%)

10 (5%)

17 (7%)

IIIA, IIIB

82 (19%)

26 (14%)

56 (23%)

IIIC

277 (64%)

136 (71%)

141 (58%)

IV

49 (11%)

19 (10%)

30 (12%)

Residual tumour size

   

0

87 (20%)

35 (18%)

52 (21%)

≤ 2 cm

141 (32%)

77 (40%)

64 (26%)

> 2 cm

207 (48%)

79 (42%)

128 (53%)

Histological type

   

serous

334 (77%)

142 (74%)

192 (79%)

endometrioid

22 (5%)

8 (4%)

14 (6%)

clear cell

15 (3%)

4 (2%)

11 (4%)

undifferentiated

33 (8%)

20 (11%)

13 (5%)

other types

31 (7%)

17 (9%)

14 (6%)

Histological grade

   

G 2

54 (13%)

24 (12%)

30 (12%)

G 3

263 (60%)

110 (58%)

153 (63%)

G 4

118 (27%)

57 (30%)

61 (25%)

Response to chemotherapy

   

complete remission

257 (59%)

124 (65%)

133 (55%)

partial remission/no change

112 (26%)

62 (32%)

50 (20%)

progression

66 (15%)

5 (3%)

61 (25%)

Platinum sensitive

129 (30%)

65 (34%)

64 (26%)

Highly platinum sensitive

83 (19%)

40 (21%)

43 (18%)

Platinum resistant

223 (51%)

86 (45%)

137 (56%)

Number of patients at risk (OS)

   

1 year

389 (89%)

180 (94%)

209 (86%)

2 years

276 (63%)

141 (74%)

135 (57%)

3 years

172 (39%)

83 (43%)

89 (36%)

4 years

116 (27%)

53 (28%)

63 (26%)

5 years

76 (17%)

31 (16%)

45 (18%)

Number of patients at risk (DFS)

   

1 years

143 (56%)

70 (56%)

73 (55%)

2 years

83 (32%)

40 (32%)

43 (32%)

3 years

61 (24%)

27 (22%)

34 (26%)

4 years

43 (17%)

17 (14%)

26 (19%)

5 years

28 (11%)

10 (8%)

18 (13%)

Follow-up time

   

Range (month)

4.4-198.3

4.8-100.6

4.4-198.3

mean

30

32.2

27.5

Outcome

   

NED

45 (10%)

27 (14%)

18 (7%)

AWD

45 (10%)

35 (18%)

10 (4%)

DOD

335 (77%)

124 (65%)

211 (87%)

DOC

10 (3%)

5 (3%)

5 (2%)

  1. PC- cyclophosphamide and cisplatin, PAC-PC plus doxorubicin, TP-taxane-platinum therapy; NED-no evidence of disease, AWD-alive with disease, DOD-died of disease, DOC-died of other causes; OS-overall survival, DFS-disease free survival
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us